Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00360724
Other study ID # # 4967/6363R
Secondary ID
Status Completed
Phase Phase 4
First received August 3, 2006
Last updated October 5, 2015
Start date August 2006
Est. completion date December 2013

Study information

Verified date October 2013
Source New York State Psychiatric Institute
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The investigators are studying a new antidepressant medicine, duloxetine, for the treatment of people with chronic depression. Duloxetine (trade name Cymbalta) was recently approved by the FDA for the treatment of major depression. The investigators are testing whether this medicine is also effective for adults with chronic depression (dysthymic disorder or dysthymia).

Chronic depression, lasting two or more years, often causes significant suffering and impairment. The investigators study involves a 6 to 10 week double-blind Initial Phase during which half of the participants will take the new medication and half will take a placebo (an inactive look-alike pill). After the Initial Phase, a 12-week Continuation Phase will begin, during which all subjects can be treated with an FDA-approved antidepressant medication.

Eligible subjects may also receive MRI scans, to help the investigators understand how antidepressants work in treating depression.


Description:

This is a 22-week study of the tolerability, dosing, and efficacy of duloxetine in chronically depressed outpatients. Participants can have Dysthymic Disorder (Dysthymia), or Depression, Not Otherwise Specified (Depression NOS).

The first 10 weeks (Acute Phase) are double blind, placebo-controlled, and the second 12 weeks (Continuation Phase) is open-label and all subjects will receive active medication.

Tests of cytokine functioning will be performed and analyzed for treatment and placebo effects.

In addition, a subset of patients will be enrolled into an Magnetic Resonance Imaging (MRI) sub-study, in which a variety of brain imaging techniques (including anatomical MRI, functional MRI (fMRI), MR Spectroscopy, and Diffusion Tensor Imaging) will be performed at baseline and week 10. Duloxetine responders will have a third MRI performed at week 22.


Recruitment information / eligibility

Status Completed
Enrollment 65
Est. completion date December 2013
Est. primary completion date December 2011
Accepts healthy volunteers No
Gender Both
Age group 20 Years to 75 Years
Eligibility Inclusion Criteria:

- age 20 to 75 years (ages 20 to 60 for MRI sub-study)

- diagnosis of dysthymic disorder (chronic depression) or depression NOS

- minimum of 2 years duration of current episode of depression

Exclusion Criteria:

- current major depression

- diagnoses including delirium, dementia, bipolar disorder, schizophrenia

- substance abuse or dependence in the past 6 months

- pregnant or nursing women

- serious risk of suicide

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Intervention

Drug:
Duloxetine (Cymbalta)
duloxetine medication up to dose of 120 mg/day

Locations

Country Name City State
United States New York State Psychiatric Institute New York New York

Sponsors (2)

Lead Sponsor Collaborator
New York State Psychiatric Institute Eli Lilly and Company

Country where clinical trial is conducted

United States, 

References & Publications (1)

Hellerstein DJ, Stewart JW, McGrath PJ, Deliyannides DA, Batchelder ST, Black SR, Withers A, O'Shea D, Chen Y. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression. J Clin Psychiatry. 2012 Jul;73(7):98 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Hamilton Depression Rating Scale (HDRS) - 24 Total Score HDRS-24 total score, standardly used rating scale for depression. Score 0-7 no depression; Score 8-16 mild depression; Score 17-23 moderate depression; Score 24 and up severe depression. Range= 0 to 75, higher score=worse depression Week 10 Yes
Primary Hamilton Depression Rating Scale (HDRS) - 24 Total Score HDRS-24 total score, standardly used rating scale for depression. Score 0-7 no depression; Score 8-16 mild depression; Score 17-23 moderate depression; Score 24 and up severe depression. Range= 0 to 75, higher score=worse depression Baseline Yes
Secondary Cornell Dysthymia Rating Scale (CDRS) CDRS is a 20-item clinician-rated inventory for chronic depressive symptoms. Each item was characterized by an explanatory or illustrative description and rated from 0 (symptom absent) to 4 (severe symptoms).
Scores from 0 to 82 with higher score indicating worse depression
Week 10 No
Secondary Global Assessment of Functioning Scale (GAF) A commonly used rating scale for global social function.
Range from 0 to 100; higher score=better functioning. 91 - 100 No symptoms. 81 - 90 Absent or minimal symptoms 71 - 80 no more than slight impairment in social, occupational, or school functioning (e.g., temporarily falling behind in schoolwork).
61 - 70 Some mild symptoms 51 - 60 Moderate symptoms 41 - 50 Serious symptoms 31 - 40 Some impairment in reality testing or communication 21 - 30 Behavior is considerably influenced by delusions or hallucinations or serious impairment, in communication or judgment 11 - 20 Some danger of hurting self or others
1 - 10 Persistent danger of severely hurting self or others or persistent inability to maintain minimal personal hygiene or serious suicidal act with clear expectation of death.
0 Inadequate information
Week 10 No
Secondary Beck Depression Inventory (BDI) Beck Depression Inventory (BDI)is a 21-question multiple-choice self-report inventory, one of the most widely used instruments for measuring the severity of depression.
When the test is scored, a value of 0 to 3 is assigned for each answer and then the total score is compared to a key to determine the depression's severity. The standard cut-offs are as follows:[7]
0-9: indicates minimal depression 10-18: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression.
Higher total scores indicate more severe depressive symptoms.
Week 10 No
Secondary Magnetic Resonance Imaging, Anatomical Chronic depression vs. normal differences: we expect to find abnormal brain region volumes in several regions compared to norms. Specifically: Frontal Cortex: decreased dorsal prefrontal volume, and reduced grey matter in subgenual prefrontal cortex; reduced orbitofrontal cortex gray matter volume; decreased hippocampal volume; decreased amygdala volume; decreased caudate volume; decreased putamen volume
treatment vs. placebo differences: following active treatment, we hypothesize that volumes will change in the direction of normal in the hippocampus, prefrontal cortex, subgenual cortex, and amygdala
responder vs. non-responder differences: greater changes in the areas found in hypothesis 2 are expected in treatment responders compared to non-responders
10 weeks, 22 weeks No
Secondary Clinical Global Impressions Improvement(CGI-I) The Clinical Global Impression - Improvement(CGI-I) is a 7-point scale that rate patient's total improvement whether or not comparing to his/her condition at baseline.
0 = Not assessed
= Very much improved
= Much improved
= Minimally improved
= No change
= Minimally worse
= Much worse
= Very much worse Higher score=greatest worsening
10 weeks No
Secondary Magnetic Resonance Imaging, Functional (fMRI) Functional brain imaging tests, including measures of cognitive conflict (Simon Task) and affective activation (Affective circumplex task) fMRI
a. Simon Task: i. We expect reduced frontal cortex activation in depressed subjects, and ii. normalization of frontal cortex activation following treatment. b. Affective Circumplex Task: i. Reduced amygdala and hippocampal activation in depressed subjects, ii. normalization of activation in these areas following treatment.
10 weeks No
Secondary Magnetic Resonance Spectroscopic Imaging (MRSI) Magnetic resonance spectroscopic imaging. We expect to find decreased levels of N-Acetyl-Aspartate (NAA) in frontal cortex (dorsal prefrontal, subgenual prefrontal cortex, and orbitofrontal cortex gray matter), as well as in hippocampus, amygdala, caudate, and putamen. 10 weeks No
Secondary Cornell Dysthymia Rating Scale (CDRS) CDRS is a 20-item clinician-rated inventory for chronic depressive symptoms. Each item was characterized by an explanatory or illustrative description and rated from 0 (symptom absent) to 4 (severe symptoms).
Scores from 0 to 82 with higher score indicating worse depression
Baseline No
Secondary Beck Depression Inventory (BDI) Beck Depression Inventory (BDI)is a 21-question multiple-choice self-report inventory, one of the most widely used instruments for measuring the severity of depression.
When the test is scored, a value of 0 to 3 is assigned for each answer and then the total score is compared to a key to determine the depression's severity. The standard cut-offs are as follows:[7]
0-9: indicates minimal depression 10-18: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression.
Higher total scores indicate more severe depressive symptoms.
Baseline No
Secondary Global Assessment of Functioning Scale (GAF) A commonly used rating scale for global social function.
Range from 0 to 100; higher score=better functioning. 91 - 100 No symptoms. 81 - 90 Absent or minimal symptoms 71 - 80 no more than slight impairment in social, occupational, or school functioning (e.g., temporarily falling behind in schoolwork).
61 - 70 Some mild symptoms 51 - 60 Moderate symptoms 41 - 50 Serious symptoms 31 - 40 Some impairment in reality testing or communication 21 - 30 Behavior is considerably influenced by delusions or hallucinations or serious impairment, in communication or judgment 11 - 20 Some danger of hurting self or others
1 - 10 Persistent danger of severely hurting self or others or persistent inability to maintain minimal personal hygiene or serious suicidal act with clear expectation of death.
0 Inadequate information
Baseline No
See also
  Status Clinical Trial Phase
Completed NCT01583400 - Enhanced Collaborative Depression Treatment in Primary Care: The RESPECT-D-E Trial N/A
Recruiting NCT00260390 - Testosterone Replacement in Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial Phase 4
Completed NCT00518986 - Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression Phase 4
Completed NCT04437485 - eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk Phase 2
Completed NCT01892124 - Motivational Interviewing and Cognitive Behavioral Therapy-based Intervention for Cardiovascular Disease Prevention Amongst American Indians With Diabetic and Depressive Symptoms N/A
Active, not recruiting NCT01473615 - Mindfulness Based Cognitive Therapy for Chronic Pain and Comorbid Unipolar Depression N/A
Completed NCT01542957 - Cognitive Therapy for Unipolar Depression: Efficacy of a Dilemma-Focused Intervention N/A
Completed NCT00619411 - Interpersonal Psychotherapy for Depressed Adolescents and Parents Phase 1
Completed NCT00225251 - Wellbutrin XL for Dysthymic Disorder Phase 4
Recruiting NCT03507114 - Rumination Focus Cognitive Behavior Therapy N/A
Recruiting NCT03917550 - RECOVERY: A Transdiagnostic Intervention for Anxiety and Depression N/A
Completed NCT00688818 - Quetiapine in Co-Morbid Depressive and Anxiety Disorders N/A
Completed NCT00220701 - Escitalopram in the Treatment of Dysthymic Disorder, Double Blind Phase 4
Completed NCT00096642 - Cognitive Behavioral Therapy for Early-Onset Depression N/A
Completed NCT02458690 - eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients Phase 2
Completed NCT00883519 - The Efficacy of Parent Involvement in the Treatment of Adolescent Depression Phase 1/Phase 2
Completed NCT01852383 - Duloxetine Treatment in Elderly With Dysthymia Phase 4
Completed NCT01561105 - Improving Depression Care for Elders: Coordinating Center N/A
Not yet recruiting NCT05118594 - Testing a Precision Psychotherapy System for Low-income Patients N/A
Completed NCT01537068 - Desvenlafaxine vs. Placebo Treatment of Chronic Depression Phase 4